105258-93-3

Basic information

• Product Name: N-CBZ-3-OXOAZETIDINE
• Synonyms: N-CBZ-3-OXOAZETIDINE;1-Cbz-3-azetidinone;3-Oxo-azetidine-1-carboxylic acid benzyl ester;1-Azetidinecarboxylic acid, 3-oxo-, phenylMethyl ester;Azetidin-3-one, N-CBZ protected;Benzyl 3-oxoazetidine-1-carboxylate, 1-[(Benzyloxy)carbonyl]-3-oxoazetidine;1-(Benzyloxycarbonyl)azetidin-3-one
• CAS NO: 105258-93-3
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.22
• Mol File: 105258-93-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 356.527 °C at 760 mmHg
• Flash Point: 169.422 °C
• Appearance: /
• Density: 1.308 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: 2-8°C
• PKA: -2.04±0.20(Predicted)
• CAS DataBase Reference: N-CBZ-3-OXOAZETIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-CBZ-3-OXOAZETIDINE(105258-93-3)
• EPA Substance Registry System: N-CBZ-3-OXOAZETIDINE(105258-93-3)

Safety Data

• Hazardous Substances Data: 105258-93-3(Hazardous Substances Data)

Usage

General Description

N-CBZ-3-OXOAZETIDINE, also known as carbobenzyloxy-3-oxoazetidine, is a chemical compound with the molecular formula C11H11NO3. It is an azetidine derivative and is commonly used in organic synthesis and pharmaceutical research. N-CBZ-3-OXOAZETIDINE has been studied for its potential pharmacological activities, including antiviral and antitumor properties. It can be used as a building block in the synthesis of various pharmaceutical compounds and can also be utilized in the preparation of peptide-based drugs. N-CBZ-3-OXOAZETIDINE is also known for its ability to form stable complexes with metal ions, making it useful in metal coordination chemistry.

InChI:InChI=1/C11H11NO3/c13-10-6-12(7-10)11(14)15-8-9-4-2-1-3-5-9/h1-5H,6-8H2

Upstream product

• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 501-53-1 benzyl chloroformate 
• 17557-84-5 3-oxoazetidine hydrochloride salt 
• 128117-22-6 1-Benzyloxycarbonyl-3-hydroxyazetidine 
• 55378-79-5 C₁₃H₁₅NO₆ 
• 67865-70-7 1-diazo-3-(N-benzyloxycarbonyl)amino-2-propanone 
• 40320-60-3 N-benzhydryl 3-azetidinone 

Downstream Products

• 934665-74-4 benzyl 3-hydroxy-3-(2-oxocyclohexyl)azetidine-1-carboxylate 
• 934665-87-9 phenylmethyl 3-hydroxy-3-{(1R)-1-methyl-2-oxo-2-[(4S)-2-oxo-4-(phenylmethyl)-1,3-oxazolidin-3-yl]ethyl}azetidine-1-carboxylate 
• 934666-11-2 phenylmethyl 3-[2-(1,3-dioxolan-2-yl)ethylidene]azetidine-1-carboxylate 
• 111491-97-5 (2-oxopropyl)carbamic acid benzyl ester 
• 934664-27-4 1,1-dimethylethyl 2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate 
• 934664-23-0 benzyl 3-methyleneazetidine-1-carboxylate 

Relevant articles and documents

Intramolecular N-H insertion of α-diazocarbonyls catalyzed by Cu(acac)2: An efficient route to derivatives of 3-oxoazetidines, 3-oxopyrrolidines and 3-oxopiperidines

Cu(acac)2 was found to be an efficient catalyst for the intramolecular N-H insertion by carbenoids. The competitive intramolecular C-H insertion by carbenoids is not a problem in the diazo decomposition reaction with Cu(acac)2 as catalyst. The reaction provided derivatives of 3-oxoazetidine, 3-oxopyrrolidine and 3-oxopiperidine in moderate to good yields.

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.